Kosta Uzelak

Kosta Uzelak

25 Jun, 2025

Kosta is an experienced IT professional based in the Netherlands, with over 12 years of specialized expertise in managing and implementing IT solutions for the pharmaceutical industry, including business-critical applications, such as RIMS, Submission and Publishing, and DMS.

As Product Owner at Celegence, Kosta oversees the continuous development and validation of innovative proprietary software applications. He is committed to delivering high-value solutions through agile methodologies, ensuring that business requirements are effectively translated into technical solutions.

He holds a Master’s degree in Business/Managerial economics from the University of Zagreb.

Other Related Articles

Beyond Document Delivery: How a Compliance-First CER Strategy Helped Achieve a Successful Notified Body Review

Blog Medical Devices

Beyond Document Delivery: How a Compliance-First CER Strategy Helped Achieve a Successful Notified Body Review

22 Jul, 2026

Responsible Integration of Artificial Intelligence in Clinical Evaluation Reports

Blog Medical Devices

Responsible Integration of Artificial Intelligence in Clinical Evaluation Reports

21 Jul, 2026

Navigating the Nagoya Protocol in Pharmaceutical Regulatory Affairs

Blog Pharmaceutical

Navigating the Nagoya Protocol in Pharmaceutical Regulatory Affairs

15 Jul, 2026

Companion Diagnostic Studies Under IVDR: Regulatory Requirements, Study Design, and Clinical Evidence Generation

Blog Medical Devices

Companion Diagnostic Studies Under IVDR: Regulatory Requirements, Study Design, and Clinical Evidence Generation

08 Jul, 2026

Beyond “Inactive”: Mastering Type IV DMFs for Excipients Using IPEC Guidance

Blog Pharmaceutical

Beyond “Inactive”: Mastering Type IV DMFs for Excipients Using IPEC Guidance

02 Jul, 2026

Ethylene Oxide in Pharmaceuticals and Consumer products – Essential Intermediate, High-Risk Exposure – A Regulatory Deep Dive

Blog Pharmaceutical

Ethylene Oxide in Pharmaceuticals and Consumer products – Essential Intermediate, High-Risk Exposure – A Regulatory Deep Dive

26 Jun, 2026

How to Address Data Consistency Challenges in EU MDR Submissions: A CAPTIS® Perspective

Blog Medical Devices

How to Address Data Consistency Challenges in EU MDR Submissions: A CAPTIS® Perspective

17 Jun, 2026

From Supplier to Label: Mastering Allergen Statements in Drugs and Cosmetics

Blog Pharmaceutical

From Supplier to Label: Mastering Allergen Statements in Drugs and Cosmetics

05 Jun, 2026

View All